JP6960415B2 - 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 - Google Patents

三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 Download PDF

Info

Publication number
JP6960415B2
JP6960415B2 JP2018560617A JP2018560617A JP6960415B2 JP 6960415 B2 JP6960415 B2 JP 6960415B2 JP 2018560617 A JP2018560617 A JP 2018560617A JP 2018560617 A JP2018560617 A JP 2018560617A JP 6960415 B2 JP6960415 B2 JP 6960415B2
Authority
JP
Japan
Prior art keywords
trigeminal
painful
trigeminal neuralgia
neuropathy
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018560617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516722A (ja
JP2019516722A5 (cg-RX-API-DMAC7.html
Inventor
チョ・ミンジェ
ファン・ソングァン
イ・ハンジュ
Original Assignee
エスケー バイオファーマスティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスケー バイオファーマスティカルズ カンパニー リミテッド filed Critical エスケー バイオファーマスティカルズ カンパニー リミテッド
Publication of JP2019516722A publication Critical patent/JP2019516722A/ja
Publication of JP2019516722A5 publication Critical patent/JP2019516722A5/ja
Application granted granted Critical
Publication of JP6960415B2 publication Critical patent/JP6960415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018560617A 2016-05-19 2017-05-18 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 Active JP6960415B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061386 2016-05-19
KR10-2016-0061386 2016-05-19
PCT/KR2017/005172 WO2017200317A1 (ko) 2016-05-19 2017-05-18 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2019516722A JP2019516722A (ja) 2019-06-20
JP2019516722A5 JP2019516722A5 (cg-RX-API-DMAC7.html) 2020-07-02
JP6960415B2 true JP6960415B2 (ja) 2021-11-05

Family

ID=60325324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560617A Active JP6960415B2 (ja) 2016-05-19 2017-05-18 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用

Country Status (14)

Country Link
US (2) US11207295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3459542B1 (cg-RX-API-DMAC7.html)
JP (1) JP6960415B2 (cg-RX-API-DMAC7.html)
KR (1) KR102421013B1 (cg-RX-API-DMAC7.html)
CN (1) CN109310669B (cg-RX-API-DMAC7.html)
AU (1) AU2017267160B2 (cg-RX-API-DMAC7.html)
CA (1) CA3024284C (cg-RX-API-DMAC7.html)
DK (1) DK3459542T3 (cg-RX-API-DMAC7.html)
ES (1) ES2887338T3 (cg-RX-API-DMAC7.html)
MX (1) MX389613B (cg-RX-API-DMAC7.html)
PL (1) PL3459542T3 (cg-RX-API-DMAC7.html)
PT (1) PT3459542T (cg-RX-API-DMAC7.html)
RU (1) RU2751504C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017200317A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
MX2021004342A (es) * 2018-10-19 2021-05-31 Sk Biopharmaceuticals Co Ltd Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
US5958949A (en) * 1996-12-31 1999-09-28 Gpi Nil Holdings Inc. N-linked ureas and carbamates of piperidyl thioesters
WO2002067922A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP4227121B2 (ja) * 2005-06-08 2009-02-18 独立行政法人科学技術振興機構 神経因性疼痛治療剤
JP5683580B2 (ja) * 2009-06-22 2015-03-11 エスケー バイオファーマシューティカル カンパニー リミテッド カルバミン酸（ｒ）−１−アリール−２−テトラゾリル−エチルエステルの製造方法
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
AU2011328009A1 (en) * 2010-11-11 2013-05-30 Akron Molecules Ag Compounds and methods for treating pain
NZ726131A (en) * 2014-05-09 2018-12-21 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine

Also Published As

Publication number Publication date
US20190175555A1 (en) 2019-06-13
KR20170131241A (ko) 2017-11-29
CN109310669B (zh) 2022-02-22
RU2751504C2 (ru) 2021-07-14
PT3459542T (pt) 2021-08-24
JP2019516722A (ja) 2019-06-20
RU2018144784A3 (cg-RX-API-DMAC7.html) 2020-08-11
US11207295B2 (en) 2021-12-28
EP3459542A4 (en) 2020-01-08
BR112018073556A2 (pt) 2019-03-19
AU2017267160B2 (en) 2022-11-10
RU2018144784A (ru) 2020-06-19
MX2018014081A (es) 2019-09-02
MX389613B (es) 2025-03-20
EP3459542B1 (en) 2021-06-30
US20220087976A1 (en) 2022-03-24
PL3459542T3 (pl) 2021-12-27
CA3024284C (en) 2024-01-23
KR102421013B1 (ko) 2022-07-14
DK3459542T3 (da) 2021-09-13
CA3024284A1 (en) 2017-11-23
EP3459542A1 (en) 2019-03-27
AU2017267160A1 (en) 2018-12-13
CN109310669A (zh) 2019-02-05
WO2017200317A1 (ko) 2017-11-23
ES2887338T3 (es) 2021-12-22

Similar Documents

Publication Publication Date Title
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
US20220087976A1 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
JP2021503010A (ja) 欠神発作又は欠神発作を示すてんかんの予防、軽減又は治療のためのカルバメート化合物の使用
KR20210062029A (ko) 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
US20220117941A1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
HK40003859A (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
HK40003859B (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
JO et al. Use of carbamate compound for preventing or treating trigeminal neuralgia
BR112018073556B1 (pt) Uso de um composto de carbamato
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP2010518052A (ja) 性機能障害の予防および治療に有用な薬物の調製のための、ニューロキニンａのｎｋ２受容体に対する化合物である拮抗薬の使用
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211011

R150 Certificate of patent or registration of utility model

Ref document number: 6960415

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250